Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a medication originally developed for the treatment of type 2 diabetes. It works by mimicking the effects of GLP-1, a natural hormone that helps regulate blood sugar levels, appetite, and digestion. Clinical trials investigating its use for weight management have shown significant reductions in body weight, raising questions about its specific effects on different fat depots. The distribution of fat, particularly abdominal fat, is a key factor in metabolic health.
Excess abdominal fat, often referred to as visceral fat, is associated with an increased risk of cardiovascular disease, type 2 diabetes, and other metabolic complications. Understanding the impact of medications like semaglutide on visceral fat is crucial for developing effective weight management strategies and improving overall metabolic health. Research into the mechanisms by which this medication influences fat distribution could lead to targeted therapies for individuals at higher risk of these conditions. This area of research has garnered significant attention due to the growing prevalence of obesity and its related health consequences.